Clinical Trials Directory

Trials / Completed

CompletedNCT00117078

Aranesp® Monthly Preference Study - 2

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
Sponsor
Amgen · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study was to evaluate subject preference for Aranesp® administered once monthly (i.e., every 4 weeks (Q4W)) or Procrit® administered once weekly (QW).

Conditions

Interventions

TypeNameDescription
DRUGAranesp®

Timeline

First posted
2005-07-04
Last updated
2008-09-30

Source: ClinicalTrials.gov record NCT00117078. Inclusion in this directory is not an endorsement.